FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA
Center | Date | Time | Location |
---|---|---|---|
CDRH | September 06, 2006 September 07, 2006 |
8:00 a.m. - 5:00
p.m. 8:00 a.m. - 5:00 p.m. |
Holiday Inn |
Agenda:
This joint committee will review and discuss peer-reviewed scientific literature
on dental amalgam devices. Dental amalgam, also called "encapsulated amalgam,"
consists of dental mercury and amalgam alloys. This joint committee will review
and discuss peer-reviewed scientific literature on dental amalgam and its potential
mercury toxicity, specifically as it relates to neurotoxic effects. Certain
consumer groups have raised concerns about the effects of using mercury as a
component of dental restorative materials; therefore, we are combining the expertise
of the Dental Products Panel of the Medical Device Advisory Committee with the
neurology expertise of the Peripheral and Central Nervous System Drugs Advisory
Committee.
Background material and meeting information will become available no later than one business day before each meeting day (Simply scroll down to the appropriate committee heading).
Procedure:
Interested persons may present data, information, or views, orally or in writing,
on issues pending before the committee. Written submissions may be made to the
contact person by August 23, 2006. On September 6 and 7, 2006, Oral presentations
from the public will be scheduled at the beginning of committee deliberations
and near the end of the deliberations. Time allotted for each
presentation may be limited. Those desiring to make formal oral presentations
should notify the contact person by August 23, 2006, and include the names and
addresses of proposed participants, and an indication of the approximate time
requested to make their presentation. Persons attending FDA's advisory committee
meetings are advised that the agency is not responsible for providing access
to electrical outlets.
FDA welcomes the attendance of the public at its advisory committee meetings
and will make every effort to accommodate persons with physical disabilities
or special needs. If you require special accommodations due to a disability,
please contact Ann Marie Williams, Conference Management Staff, 240-276-0450
ext. 113, at least 7 days in advance of the meeting.
Contact Person:
Michael E. Adjodha, Center for Devices and Radiological Health (HFZ-480), Food
and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-827-5283,
ext. 123, e-mail: Michael.Adjodha@fda.hhs.gov
Advisory Committee Telephone Information Line:
Please call the Information Line for up-to-date information on this
meeting, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 3014512518.